TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04804332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative hysteroscopy
Description: Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectant management
Description: No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
Study: NCT06286566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement with soi surface in diabetic subjects
Description: Implants placement with SOI surface in subjects with diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement with soi surface in healthy subjects
Description: Implants placement with SOI surface in subjects without diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
Study: NCT06703060

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer Navigation Group
Description: Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation Group
Description: Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
Study: NCT06697184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally
Study: NCT05439720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
Study: NCT04881526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-beta-hydroxybutyrate
Description: Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric flavored water with medium-chain triglyceride oil.
Study: NCT05539183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Blood withdrawal
Study: NCT04699981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)
Description: For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)
Description: A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool.
Study: NCT05228119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
Study: NCT06697184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally
Study: NCT06716645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Robitussin Maximum Strength Cough and Chest Congestion DM
Description: Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Robitussin Maximum Strength Cough and Chest Congestion DM
Description: Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Robitussin Maximum Strength Nighttime Cough DM
Description: Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
Study: NCT06724640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499 Injection
Description: VH4011499 Injection will be administered either subcutaneously or intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VH4011499 Injection
Description: Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
Study: NCT06722586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus two pills (1mg) per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two pills per day
Study: NCT06733428

Intervention type: DEVICE
Intervention: Pachymeter
Description: Measure the thickness of the cornea

Intervention type: DEVICE
Intervention: Pachymeter
Description: Measure the thickness of the cornea

Intervention type: DEVICE
Intervention: Pachymeter
Description: Measure the thickness of the cornea
Study: NCT06746688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ES2B-C001
Description: Vaccine; Administration with or without Montanide™ every third week for a total of five vaccinations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ES2B-C001
Description: Vaccine; Administration with or without Montanide™ every third week for a total of five vaccinations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ES2B-C001
Description: Vaccine; Administration with or without Montanide™ every third week for a total of five vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51 VD
Description: Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51 VD
Description: Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51 VD
Description: Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.
Study: NCT06766500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets
Description: 1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synjardy® 5 mg/850 mg film-coated tablets
Description: 1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets
Study: NCT06769100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KET)
Description: - Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester + Whey Protein (KET+PRO)
Description: * Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein (PRO)
Description: * 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavour matched placebo (CON)
Description: - Flavoured water (non-caloric bitter + citrus flavours)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: - 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: - 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.
Study: NCT05820529

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adenoidectomy
Description: removal of adenoid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adenoidectomy
Description: removal of adenoid
Study: NCT06430151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CUE1
Description: Sternal worn focused vibrotactile stimulation and cueing device
Study: NCT05571761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program
Description: The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive stimulation program
Description: The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality.
Study: NCT05909306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
Study: NCT05820529

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tonsillectomy
Description: removal of tonsil

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tonsillectomy
Description: removal of tonsil
Study: NCT06769100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: - 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: - 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.
Study: NCT06772779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: single oral dose
Study: NCT06773221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar 64mg
Description: Chiglitazar 64mg, oral, qd, for 72 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, qd, for 72 weeks
Study: NCT06772844

Intervention type: DIAGNOSTIC_TEST
Intervention: fecal DNA methylation testing
Description: Three rounds of screening were performed. In the first year, colonoscopy was conducted along with concurrent fecal DNA testing performed prior to the colonoscopy. In the second year, fecal DNA testing was performed only if no polyps were detected during the colonoscopy in the first year; otherwise, both colonoscopy and fecal DNA testing were conducted. In the third year, a colonoscopy was performed with concurrent fecal DNA testing conducted before the procedure
Study: NCT06772168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG190303(Dapagliflozin/Rosuvastatin)
Description: 0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator 1: Dapagliflozin/Rosuvastatin placebo
Description: 0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin/Dapagliflozin placebo
Description: 0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
Study: NCT06770075

Intervention type: OTHER
Intervention: Observational
Description: Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.
Study: NCT06772896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reordered PHQ-8
Description: Participants will be administered the PHQ-8 somatic items separately from the psychological items, outside the context of a depression questionnaire.
Study: NCT06775288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia prevention and awareness program (HypoPAP)
Description: Online hypoglycemia prevention and awareness training Supporting the prevention of hypoglycemia with the use of evidence-based diabetes-friendly plates Encouraging physical activity and supporting glycemic control with a pedometer Filling in a weekly problem-solving notebook Conducting weekly online problem-solving meetings Online counseling service when needed
Study: NCT06776393

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound
Description: Dynamic translaryngeal Ultrasound Motion mode ultrasound of the laryngeal region during phonation Acoustic recordings VHI questionnaires
Study: NCT06775405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Study: NCT06776705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity transcranial ultrasound stimulation
Description: Low-intensity TUS, as an advanced modality of transcranial brain stimulation, enables to stimulate the deep brain structures with optimized focality and specific frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-intensity transcranial ultrasound stimulation
Description: Low-intensity TUS, as an advanced modality of transcranial brain stimulation, enables to stimulate the deep brain structures with optimized focality and specific frequency.
Study: NCT06776991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment - Behavioral (PAT-B)
Description: 8 therapy sessions conducted individually with a therapist. Focuses on improving reward processing to increase positive emotional experience. Specific techniques include psychoeducation on mood cycle and positive emotions, mood monitoring, behavioral activation, and imaginal recounting and savoring of behavioral activation events. Intervention includes between-session practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Treatment
Description: 8 therapy sessions conducted individually with a therapist. Focuses on mindfulness and relaxation skills. Specific techniques include mindfulness approaches from dialectical behavior therapy, diaphragmatic breathing, and progressive muscle relaxation. Intervention includes between-session practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: 8 therapy sessions conducted individually with a therapist using the inhibitory retrieval model of exposure therapy. Sessions are designed to include four exposures each (32 exposures total). Each exposure is a public speech delivered to an audience. Goal of this treatment is to reduce public speaking anxiety. Principles of exposure therapy that will be incorporated are maximizing prediction error, maintaining attention to the situation/stimuli that are perceived predictors of the feared outcome (e.g., social rejection), removing safety signals, variability, engaging in post-exposure rehearsal/consolidation, deepened extinction, and positive occasion setter extinction. Intervention does not include between-session practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: 8 therapy sessions conducted individually with a therapist using the inhibitory retrieval model of exposure therapy. Sessions are designed to include four exposures each (32 exposures total). Each exposure is a public speech delivered to an audience. Goal of this treatment is to reduce public speaking anxiety. Principles of exposure therapy that will be incorporated are maximizing prediction error, maintaining attention to the situation/stimuli that are perceived predictors of the feared outcome (e.g., social rejection), removing safety signals, variability, engaging in post-exposure rehearsal/consolidation, deepened extinction, and positive occasion setter extinction. Intervention does not include between-session practice.
Study: NCT05429203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenoscope with single-use distal cover
Description: Newer duodenoscope with a single-use distal cover

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional duodenoscope
Description: Conventional duodenoscope with standard methods of reprocessing
Study: NCT04898023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc-green tea extract-ascorbic acid
Description: Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded capsules containing microcrystalline cellulose.
Study: NCT04896385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.